Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib and Tazemetostat in mCRPC
NCT04846478Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of talazoparib and tazemetostat in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Dose Limiting Toxicity at 28 days and Treatment-Related Adverse Events at 2 years. Started Jun 2021; status: active, not recruiting.
02
Drugs
talazoparibtazemetostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04846478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04846478.